A single dose of epidermicin NI01 is sufficient to eradicate MRSA from the nares of cotton rats
dc.contributor.author | Halliwell, S | |
dc.contributor.author | Warn, P | |
dc.contributor.author | Sattar, A | |
dc.contributor.author | Derrick, JP | |
dc.contributor.author | Upton, Mathew | |
dc.date.accessioned | 2017-03-06T14:49:47Z | |
dc.date.accessioned | 2017-03-06T14:50:07Z | |
dc.date.available | 2017-03-06T14:49:47Z | |
dc.date.available | 2017-03-06T14:50:07Z | |
dc.date.issued | 2016-12-13 | |
dc.identifier.issn | 0305-7453 | |
dc.identifier.issn | 1460-2091 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/8589 | |
dc.description.abstract |
OBJECTIVES: To investigate the efficacy of a potent novel antimicrobial protein of mass 6 kDa, epidermicin NI01, for eradicating the nasal burden of MRSA in a cotton rat ( Sigmodon hispidus ) model. METHODS: MRSA strain ATCC 43300 was used to establish a robust colonization of cotton rat nares. This model was used to evaluate the efficacy of topical 0.04% and 0.2% epidermicin NI01, administered twice daily for 3 days consecutively, and topical 0.8% epidermicin NI01 administered once, for reducing nasal MRSA burden. Control groups remained untreated or were administered vehicle only (0.5% hydroxypropylmethylcellulose) or 2% mupirocin twice daily for 3 days. The experiment was terminated at day 5 and MRSA quantitative counts were determined. Tissues recovered from animals treated with 0.2% epidermicin twice daily for 3 days were examined for histological changes. RESULTS: Mupirocin treatment resulted in a reduction in burden of log 10 (log R) of 2.59 cfu/nares compared with vehicle ( P < 0.0001). Epidermicin NI01 administered once at 0.8% showed excellent efficacy, resulting in a log R of 2.10 cfu/nares ( P = 0.0004), which was equivalent to mupirocin. Epidermicin NI01 administered at 0.2% or 0.04% twice daily for 3 days did not have a significant impact on the tissue burden recovered from the nares. Mild to marked histological abnormalities were noted, but these were determined to be reversible. CONCLUSION: A single dose of topical epidermicin NI01 was as effective as mupirocin administered twice daily for 3 days in eradication of MRSA from the nares of cotton rats. This justifies further development of epidermicin for this indication. | |
dc.format.extent | dkw457-dkw457 | |
dc.format.medium | ||
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Oxford University Press (OUP) | |
dc.relation.replaces | http://hdl.handle.net/10026.1/8588 | |
dc.relation.replaces | 10026.1/8588 | |
dc.subject | Administration, Topical | |
dc.subject | Animals | |
dc.subject | Antimicrobial Cationic Peptides | |
dc.subject | Bacterial Load | |
dc.subject | Bacteriocins | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Methicillin-Resistant Staphylococcus aureus | |
dc.subject | Mupirocin | |
dc.subject | Nose | |
dc.subject | Rats | |
dc.subject | Sigmodontinae | |
dc.subject | Staphylococcal Infections | |
dc.title | A single dose of epidermicin NI01 is sufficient to eradicate MRSA from the nares of cotton rats | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398038800017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 3 | |
plymouth.volume | 72 | |
plymouth.publication-status | Published online | |
plymouth.journal | Journal of Antimicrobial Chemotherapy | |
dc.identifier.doi | 10.1093/jac/dkw457 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Biomedical Sciences | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2016-09-29 | |
dc.identifier.eissn | 1460-2091 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.funder | Biotechnology and Biological Sciences Research Council | |
rioxxterms.identifier.project | Development of epidermicin NI01 for nasal decolonization | |
rioxxterms.versionofrecord | 10.1093/jac/dkw457 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-12-13 | |
rioxxterms.type | Journal Article/Review | |
plymouth.funder | Development of epidermicin NI01 for nasal decolonization::Biotechnology and Biological Sciences Research Council | |
plymouth.oa-location | https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkw457 |